Pharmacotherapy of head and neck squamous cell carcinoma

Quintin Pan, Michael Gorin, Theodoros N. Teknos

Research output: Contribution to journalReview article

Abstract

Background: The clinical management of locally advanced head and neck squamous cell carcinoma (HNSCC) is a challenging problem and requires a multidisciplinary approach. Historically, locally advanced HNSCC has been primarily managed with surgery and radiation (RT). The integration of pharmacotherapy has rapidly expanded over the years into the multimodality treatment paradigm of locally advanced HNSCC. Objective: The studies leading to the adoption of the current standard of care for locally advanced HNSCC are discussed. In addition, the limitations of these various treatment approaches are presented. Methods: An extensive literature search was conducted using the PubMed database for studies published before January 2009. The keywords used for this search were: head and neck neoplasms, chemoradiation, adjuvant chemotherapy, induction chemotherapy, EGFR inhibitor, cisplatin, carboplatin, paclitaxel, docetaxel, 5-fluorouracil, and cetuximab. Publications of randomized clinical trials and other supporting references leading to the current standard of care were particularly selected and discussed in this review. Conclusions: Various single-agent and multi-agent chemotherapeutic regimens have been examined in the context of randomized clinical trials in locally advanced HNSCC for definitive, induction and adjuvant settings. Results from these clinical trials support the use of cisplatin-based chemoradiation as the standard of care for the definitive and adjuvant settings. Recent evidence indicates that cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is highly active as a single agent and in combination with standard chemotherapy and/or RT. Future studies should focus to determine the optimal pharmacotherapeutic regimens for use in locally advanced HNSCC.

Original languageEnglish (US)
Pages (from-to)2291-2302
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number14
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Drug Therapy
Standard of Care
docetaxel
Epidermal Growth Factor Receptor
Randomized Controlled Trials
Radiation
Induction Chemotherapy
Carboplatin
Adjuvant Chemotherapy
Head and Neck Neoplasms
PubMed
Fluorouracil
Cisplatin
Publications
Carcinoma, squamous cell of head and neck
Clinical Trials
Databases
Therapeutics
Cetuximab

Keywords

  • Adjuvant chemotherapy
  • Concurrent chemoradiation
  • Head and neck neoplasms
  • Induction chemotherapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacotherapy of head and neck squamous cell carcinoma. / Pan, Quintin; Gorin, Michael; Teknos, Theodoros N.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 14, 01.10.2009, p. 2291-2302.

Research output: Contribution to journalReview article

Pan, Quintin ; Gorin, Michael ; Teknos, Theodoros N. / Pharmacotherapy of head and neck squamous cell carcinoma. In: Expert Opinion on Pharmacotherapy. 2009 ; Vol. 10, No. 14. pp. 2291-2302.
@article{c0d303dc49334e30bc4ea4b919204ae2,
title = "Pharmacotherapy of head and neck squamous cell carcinoma",
abstract = "Background: The clinical management of locally advanced head and neck squamous cell carcinoma (HNSCC) is a challenging problem and requires a multidisciplinary approach. Historically, locally advanced HNSCC has been primarily managed with surgery and radiation (RT). The integration of pharmacotherapy has rapidly expanded over the years into the multimodality treatment paradigm of locally advanced HNSCC. Objective: The studies leading to the adoption of the current standard of care for locally advanced HNSCC are discussed. In addition, the limitations of these various treatment approaches are presented. Methods: An extensive literature search was conducted using the PubMed database for studies published before January 2009. The keywords used for this search were: head and neck neoplasms, chemoradiation, adjuvant chemotherapy, induction chemotherapy, EGFR inhibitor, cisplatin, carboplatin, paclitaxel, docetaxel, 5-fluorouracil, and cetuximab. Publications of randomized clinical trials and other supporting references leading to the current standard of care were particularly selected and discussed in this review. Conclusions: Various single-agent and multi-agent chemotherapeutic regimens have been examined in the context of randomized clinical trials in locally advanced HNSCC for definitive, induction and adjuvant settings. Results from these clinical trials support the use of cisplatin-based chemoradiation as the standard of care for the definitive and adjuvant settings. Recent evidence indicates that cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is highly active as a single agent and in combination with standard chemotherapy and/or RT. Future studies should focus to determine the optimal pharmacotherapeutic regimens for use in locally advanced HNSCC.",
keywords = "Adjuvant chemotherapy, Concurrent chemoradiation, Head and neck neoplasms, Induction chemotherapy",
author = "Quintin Pan and Michael Gorin and Teknos, {Theodoros N.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1517/14656560903136754",
language = "English (US)",
volume = "10",
pages = "2291--2302",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "14",

}

TY - JOUR

T1 - Pharmacotherapy of head and neck squamous cell carcinoma

AU - Pan, Quintin

AU - Gorin, Michael

AU - Teknos, Theodoros N.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - Background: The clinical management of locally advanced head and neck squamous cell carcinoma (HNSCC) is a challenging problem and requires a multidisciplinary approach. Historically, locally advanced HNSCC has been primarily managed with surgery and radiation (RT). The integration of pharmacotherapy has rapidly expanded over the years into the multimodality treatment paradigm of locally advanced HNSCC. Objective: The studies leading to the adoption of the current standard of care for locally advanced HNSCC are discussed. In addition, the limitations of these various treatment approaches are presented. Methods: An extensive literature search was conducted using the PubMed database for studies published before January 2009. The keywords used for this search were: head and neck neoplasms, chemoradiation, adjuvant chemotherapy, induction chemotherapy, EGFR inhibitor, cisplatin, carboplatin, paclitaxel, docetaxel, 5-fluorouracil, and cetuximab. Publications of randomized clinical trials and other supporting references leading to the current standard of care were particularly selected and discussed in this review. Conclusions: Various single-agent and multi-agent chemotherapeutic regimens have been examined in the context of randomized clinical trials in locally advanced HNSCC for definitive, induction and adjuvant settings. Results from these clinical trials support the use of cisplatin-based chemoradiation as the standard of care for the definitive and adjuvant settings. Recent evidence indicates that cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is highly active as a single agent and in combination with standard chemotherapy and/or RT. Future studies should focus to determine the optimal pharmacotherapeutic regimens for use in locally advanced HNSCC.

AB - Background: The clinical management of locally advanced head and neck squamous cell carcinoma (HNSCC) is a challenging problem and requires a multidisciplinary approach. Historically, locally advanced HNSCC has been primarily managed with surgery and radiation (RT). The integration of pharmacotherapy has rapidly expanded over the years into the multimodality treatment paradigm of locally advanced HNSCC. Objective: The studies leading to the adoption of the current standard of care for locally advanced HNSCC are discussed. In addition, the limitations of these various treatment approaches are presented. Methods: An extensive literature search was conducted using the PubMed database for studies published before January 2009. The keywords used for this search were: head and neck neoplasms, chemoradiation, adjuvant chemotherapy, induction chemotherapy, EGFR inhibitor, cisplatin, carboplatin, paclitaxel, docetaxel, 5-fluorouracil, and cetuximab. Publications of randomized clinical trials and other supporting references leading to the current standard of care were particularly selected and discussed in this review. Conclusions: Various single-agent and multi-agent chemotherapeutic regimens have been examined in the context of randomized clinical trials in locally advanced HNSCC for definitive, induction and adjuvant settings. Results from these clinical trials support the use of cisplatin-based chemoradiation as the standard of care for the definitive and adjuvant settings. Recent evidence indicates that cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is highly active as a single agent and in combination with standard chemotherapy and/or RT. Future studies should focus to determine the optimal pharmacotherapeutic regimens for use in locally advanced HNSCC.

KW - Adjuvant chemotherapy

KW - Concurrent chemoradiation

KW - Head and neck neoplasms

KW - Induction chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=70349383025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349383025&partnerID=8YFLogxK

U2 - 10.1517/14656560903136754

DO - 10.1517/14656560903136754

M3 - Review article

VL - 10

SP - 2291

EP - 2302

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 14

ER -